45 reports

  • Focuses on improving its position in the global diabetes drugs market

About Type 2 Diabetes Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients' blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types: - Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas...

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • PROVIDES A SWOT ANALYSIS OF ELI LILLY. TABLE 114: ELI LILLY SWOT ANALYSIS, 2016
  • 10.3.2 NOVO NORDISK

ONE SUBJECT RECEIVING FORXIGA EXPERIENCED A LIVER AE WITH DIAGNOSES OF DRUG-INDUCED HEPATITIS AND/ OR AUTOIMMUNE HEPATITIS.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

MOST NOTABLY, THESE PATIENTS TEST POSITIVE FOR AUTO-ANTIBODIES, SUGGESTING THAT, AS WITH T##DM, LADA IS AN AUTOIMMUNE DISEASE.

  • Type 2 Diabetes
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.

SEMINARS IN LIVER DISEASE; ##(##): ##-##.

  • Type 2 Diabetes
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.

OTHER CONDITIONS THAT MAY CONTRIBUTE TO SLOW HEALING OR A POOR RESPONSE TO THERAPY, SUCH AS INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) OR AN AUTOIMMUNE DISEASE, MAY ALSO BE EXCLUSIONS TO PARTICIPATION, IN ADDITION TO BEING ON RADIATION THERAPY OR CHEMOTHERAPY.

  • Type 2 Diabetes
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Osiris Therapeutics, Inc.
  • Smith & Nephew Plc
  • Trial Results

Nephropathy Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Nephropathy Global Clinical Trials Review, H2, 2015" provides an overview of Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Nephropathy. Report includes an overview...

  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

WHEN BLYS IS OVER-EXPRESSED, IT LEADS TO THE DEVELOPMENT OF AUTOIMMUNE DISEASES.

  • Autoimmune Disease
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • DIABETIC FOOT ULCERS - PIPELINE BY PROMETIC LIFE SCIENCES INC, H1 2018
  • DIABETIC FOOT ULCERS - PIPELINE BY SERODUS ASA, H1 2018

The company develops products for fibrosis, anemia, autoimmune diseases, inflammation, and nephropathies.

  • Chronic Disease
  • Therapy
  • Type 2 Diabetes
  • Wound Care
  • ProMetic Life Sciences Inc.

When BLyS is over-expressed, it leads to the development of autoimmune diseases.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • ChemoCentryx, Inc.
  • DIABETIC FOOT ULCERS - PIPELINE BY PHERECYDES PHARMA SA, H2 2018
  • DIABETIC FOOT ULCERS - PIPELINE BY ONENESS BIOTECH CO LTD, H2 2018

The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies.

  • Chronic Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • ViroMed Co., Ltd.
  • Research and Development Brief
  • PBI-4547 - DRUG PROFILE

Diabetic Nephropathy - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape. Diabetic nephropathy...

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative

The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines.

  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • ViroMed Co., Ltd.

Current therapies for autoimmune diseases are only modestly successful with significant adverse side effects, including immune suppression and malignancies.

  • Chronic Disease
  • Type 2 Diabetes
  • World
  • Product Initiative
  • BioTherapeutics Inc.
  • TNFR X TWEAKR - DRUG PROFILE
  • REDX-06109 - DRUG PROFILE

The company develops products for fibrosis, anemia, autoimmune diseases, inflammation, and nephropathies.

  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • ProMetic Life Sciences Inc.

The company offers medicines for prevention of infectious disease, treatment of autoimmune and inflammatory diseases, and treatment of cancer.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative

Hatfield advanced a robust pipeline of internally discovered first-in-class compounds, drove initial company growth through a series of high-value pharmaceutical partnering deals, and focused resources on developing the company' s wholly-owned autoimmune disease assets.

  • Healthcare
  • Type 2 Diabetes
  • United States
  • Company
  • Zafgen, Inc.

The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines.

  • Neurological Disorder
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • ViroMed Co., Ltd.

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Chemotherapy
  • Clinical Trial
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PERIPHERAL NEUROPATHY (SENSORY NEUROPATHY) - PIPELINE BY POLYNEURON PHARMACEUTICALS AG, H2 2016
  • PERIPHERAL NEUROPATHY (SENSORY NEUROPATHY) - PIPELINE BY MITSUBISHI TANABE PHARMA CORPORATION, H2 2016

The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines.

  • Neurological Disorder
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Chemotherapy
  • Clinical Trial
  • Type 2 Diabetes
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Acthar Gel CHART Trial Results Alert Rigel Pharmaceuticals, Inc., announced topline data from its proof-of-concept Phase ## study of fostamatinib in patients with IgA nephropathy (IgAN), an orphan autoimmune disease of the kidneys.

  • Clinical Trial
  • Drug Discovery And Development
  • Type 2 Diabetes
  • World
  • Product Initiative
  • 6 Key Events and History

Those include- LX##, an orally-delivered small molecule compound for the treatment of irritable Other Programs LX##, an orally-delivered small molecule compound for the of treatment bowel syndrome autoimmune disease topically-delivered small molecule compound for LX##, the of

  • Diabetes
  • Endocrine Disease
  • Pharmaceutical
  • Type 2 Diabetes
  • Lexicon Pharmaceuticals, Inc.
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY BIRCHBIOMED INC, H2 2016

It develops and offers products and technologies for the treatment of autoimmune diseases.

  • Biotechnology
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY PROMETIC LIFE SCIENCES INC
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY REATA PHARMACEUTICALS INC

The company' s products are used for the treatment and detection of cancers, the treatment of inflammatory, autoimmune diseases, and ischemic heart disease.

  • Chronic Disease
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • DIABETIC RETINOPATHY - PIPELINE BY MINGSIGHT PHARMACEUTICALS
  • DIABETIC RETINOPATHY - PIPELINE BY MABION SA

It is caused mainly by autoimmune disease, viral infection, and aging.

  • Ophthalmology
  • Type 2 Diabetes
  • Company
  • Product Initiative
  • Allergan plc

The invention relates to toxin peptide therapeutic agents for the treatment of autoimmune diseases.

  • Cancer
  • Therapy
  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • CIBINETIDE - DRUG PROFILE

t and SGK## which treats autoimmune disease and cancer.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

Most notably, these patients test positive for auto-antibodies, suggesting that, as with T##DM, LADA is an autoimmune disease.

  • Insulin
  • Pathology
  • Type 2 Diabetes
  • World
  • Deals & Alliance

The patent' s principal claims cover method of use for GR-MD-## in patients with an autoimmune disease.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines.

  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • DiaMedica Inc.